Author: Lane, Morgan D.; Kishnani, Sujata; Udemadu, Obianuju; Danquah, Samuel Eshun; Treadway, Robert M.; Langman, Aaliyah; Balevic, Stephen; Jackson, Wesley M.; Laughon, Matthew; Hornik, Christoph P.; Greenberg, Rachel G.; Clark, Reese H.; Zimmerman, Kanecia O.
Title: Comparative efficacy and safety of late surfactant preparations: a retrospective study Cord-id: hb8lf7ui Document date: 2021_7_20
ID: hb8lf7ui
Snippet: OBJECTIVE: Characterize the use, efficacy, and safety of poractant alfa and calfactant surfactants compared to beractant in preterm infants receiving late surfactant. STUDY DESIGN: We included infants <37 weeks gestational age (GA) discharged from Pediatrix Medical Group-managed neonatal intensive care units (1997–2017). Efficacy and safety outcomes of interest were analyzed. RESULTS: Of 184,770 infants administered surfactant at any time, 7846 (4.23%) received late surfactant at a median (25t
Document: OBJECTIVE: Characterize the use, efficacy, and safety of poractant alfa and calfactant surfactants compared to beractant in preterm infants receiving late surfactant. STUDY DESIGN: We included infants <37 weeks gestational age (GA) discharged from Pediatrix Medical Group-managed neonatal intensive care units (1997–2017). Efficacy and safety outcomes of interest were analyzed. RESULTS: Of 184,770 infants administered surfactant at any time, 7846 (4.23%) received late surfactant at a median (25th, 75th percentile) PNA of 8 days (3, 22); specifically, 2976 received poractant alfa (38%), 2890 beractant (37%), and 1936 calfactant (25%). We identified no significant differences in composite efficacy or safety outcomes between surfactants in the primary analysis, but 33–36 week GA infants administered poractant alfa had significantly greater odds of developing a safety event. CONCLUSIONS: Compared to beractant, there is no evidence of overall superior efficacy or safety of poractant alfa.
Search related documents:
Co phrase search for related documents- additional study and adjusted analysis: 1, 2
- additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- additional study and low incidence: 1
- additional study and lung compliance: 1
- additional study and lung disease: 1, 2, 3, 4
- adjusted analysis and administrative database: 1
- adjusted analysis and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- adjusted analysis and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- adjusted analysis and low incidence: 1, 2
- adjusted analysis and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- administrative database and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- administrative database and logistic regression model: 1
- administrative database and lung disease: 1, 2
- logistic regression and low incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- logistic regression and lung compliance: 1, 2, 3, 4
- logistic regression and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- logistic regression model and low incidence: 1, 2
- logistic regression model and lung compliance: 1
- logistic regression model and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date